SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responses Authors: Gao Yu, Yusheng Liang, Weize Yu, Gaojian Zhuang, Bing Li, Jiayi Huang, Jinghao Zheng, Xuanqi Yang, Leyun Wen, Xiaoming Tan, Yuan Zhang Published: 2026 ABSTRACT AbstractDespite the achievements of immunotherapy in the treatment of cancer, overcoming the immune resistance is still an unmet challenge. Dendritic cells (DCs) dysfunction plays a pivotal role in tumor immunoevasion. Previous study uncovered that targeting src homologous region 2 protein tyrosine phosphatase (SHP1) improved anti-PD-1 therapy efficacy in breast cancer by reinvigorating DCs, but the detailed mechanisms remained unclear. Here, we investigated the function of SHP1 in enabling tumor immune escape and suppressing memory T cell formation. Deficiency of SHP1 augmented the activation and antigen-presenting function of dendritic cells, which consequently suppressed the growth of B16-F10 and EMT6 models. We validated this enhanced DC-mediated anti-tumor immunity using conditional knockout mice of SHP1. These results suggested that SHP1 acts as a critical promoter of tumor immune escape. Combining transcriptomic analysis with DC-specific SHP1 deletion, we demonstrated that SHP1 deficiency augments DC immunogenicity via the IFN-γ-JAK1/2-STAT1 pathway. Furthermore, SHP1 blockade promoted the generation of central memory CD8+ T cells, through upregulating the expression of TCF-1, a transcription factor essential for memory lineage commitment. In summary, our research identifies SHP1 as a critical intracellular checkpoint that promotes tumor immune evasion by concurrently suppressing DC antigen presentation and the formation of central memory CD8+ T cells, nominating it as a promising therapeutic target for immunotherapy-resistant cancers. Subject terms: Cancer immunotherapy, Antigen processing and presentation Introduction As a leading cause of death globally, cancer poses a defining public health challenge, imposing a multifaceted burden on individual lives, healthcare systems, and socioeconomic development. Its progression is influenced by a myriad of genetic and epigenetic factors. Moreover, remodeling of the tumor microenvironment (TME) and the dynamic interactions between cells and the extracellular matrix are also crucial drivers of tumor progression [1]. TME is a complex ecosystem composed of cancer cells, stromal cells (e.g., fibroblasts), and a diverse array of immune cells such as macrophages, neutrophils, and dendritic cells, which collectively shape tumor progression and metastasis [2]. Immunotherapy, which aims to enhance the body’s natural defenses to eliminate cancer cells, has emerged as a promising therapeutic option. This therapeutic approach is distinguished by its high specificity, efficacy, and relatively minimal side effects [3, 4]. Several forms of immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapy [5, 6], have demonstrated remarkable and durable clinical responses in various malignancies. However, the effectiveness of these treatments varies among individuals, with only a portion of cancer patients deriving significant benefit. A key factor contributing to this variability is tumor immune evasion, which undermines immune surveillance and therapeutic interventions [7, 8]. Tumor immunoevasion involves a range of complex mechanisms by which tumor cells escape recognition and destruction by the immune system. This process is crucial in enabling tumor cells to grow and metastasize continuously [7]. Dendritic cells (DCs) represent the most potent antigen-presenting cells, possessing the capability to recognize and present tumor antigens [9, 10]. They are classified into classical dendritic cells (cDCs) and plasmacytoid dendritic cells (pDC) [11], and play a pivotal role in the initiation and regulation of both innate and adaptive immunity. By recognizing and presenting tumor antigens, DCs activate lymphocytes, thereby facilitating a targeted immune response against the tumor [12]. However, within the immunosuppressive TME, tumor-infiltrating DCs often exhibit impaired antigen processing and presentation, which allows tumor cells to evade immune detection. These DCs frequently exhibit severe functional impairments or develop tolerance, which prevents them from inducing a robust immune response. Consequently, this limitation significantly constrains the efficacy of T cell-based therapies [13]. Identifying key factors that regulate DC function and exploring their roles within the TME is of significant clinical importance. Previous studies have demonstrated that Vitamin E (VitE) significantly enhanced PD-1/PD-L1 response by activating DCs. In addition, reverse phase protein array analysis indicates that VitE reduces the phosphorylation levels of Src homology region 2 domain-containing phosphatase-1 (SHP1), encoded by the Ptpn6 gene, at tyrosine 564 (SHP1-pY564) [14]. SHP1 is a cytosolic tyrosine phosphokinase that affects tumor cell proliferation, survival, migration, and invasion [15]. Nevertheless, the specific mechanism of SHP1 in DCs and its functional contribution to T cell-mediated antitumor immunity remain to be fully elucidated. Memory T cells, including central memory T cells (TCM) and effector memory T cells (TEM), persist long after antigen clearance and enable rapid and robust immune responses upon antigen reencounter. In addition to their canonical role in priming naive T cells through antigen presentation, DCs also serve as key regulators of memory T cell effector functions, as optimal memory T cell responses remain dependent on innate cytokines and costimulatory signals provided by antigen-presenting cells, including DCs [16]. This study aims to elucidate how SHP1 in DCs regulates antigen presentation and DC activation, thereby suppressing memory T cell generation and effector function within the TME and contributing to subsequent immune escape. Understanding these mechanisms is essential for developing novel therapeutic strategies to enhance anti-tumor immunity and improve the efficacy of immunotherapies. Methods Mouse models Female wild-type C57BL/6 J and BALB/c mice were derived from Guangdong Medical Laboratory Animal Center and Guangdong GemPharmatech Co., Ltd (Guangdong, China). Ptpn6flox/+, CD11ccre and OT-1 mice were purchased from Cyagen Biosciences Inc. (Guangzhou, China). Ptpn6flox/+ mice were intercrossed to obtain Ptpn6flox/+ and Ptpn6flox/flox offspring. These were then bred with CD11ccre mice to generate conditional knockout mice (CD11ccre-Ptpn6flox/flox, cKO) with DC-conditional PTPN6 deletion, along with control mice (Ptpn6flox/+, CTL). For genotyping, tail DNA was extracted with NaOH lysis buffer and amplified with gene-specific primers (Supplementary Table S1). Cell lines The HEK293T, DC2.4, B16-F10, EMT6, and EO771 were purchased from American Type Culture Collection. All cell lines were tested for mycoplasma contamination. Tissue microarray (TMA), immunofluorescence (IF) and immunohistochemistry (IHC) TMAs (triple negative breast cancer (TNBC), HBreD060Bc01) were purchased from Outdo Biotech (Shanghai, China). The supplier confirmed that all samples were collected with informed consent from patients. The IF was performed by Servicebio (Wuhan, China), using fluorescent homologous double-labeling staining to detect the co-localization positive rate of SHP1 (red) and CD14 (green). IHC staining was performed as previously described [17]. The primary antibodies used are listed in Supplementary Table S1. CRISPR-Cas9–mediated gene knockout in the DC2.4 cell line DC2.4-KO-Ptpn6 cells were constructed using lentivirus containing the CRISPR/Cas9 gene-editing system to target the murine Ptpn6 (15170) gene, which was purchased from GeneChem Co, Ltd. (Shanghai, China). Antigen processing/presentation of DCs and activation of the JAK1/2-STAT1 signaling pathway For in vitro antigen presentation experiments, DC2.4 cells were stimulated with 100 ng/ml lipopolysaccharide (LPS) for 16 h to induce maturation, followed by treatment with 250 μg/ml ovalbumins (OVA) (vac-stova, InvivoGen) for 24 h. Surface expressions of SIINFEKL-loaded MHC-I complexes, CD40, and MHC-II on treated cells were determined by fluorescence activated cell sorting (FACS). For in vitro activation of the JAK1/2-STAT1 signaling pathway, DC2.4 cells and bone marrow-derived dendritic cells (BMDCs) were stimulated with 100 ng/ml mouse IFN-γ (UA040065, UA BIOSCIENCE) for 24 h and harvested 24 h post-stimulation for protein analysis. Western blot Cells were lysed in lysis buffer (abs47014880, Absin) containing protease inhibitor and phosphatase inhibitor. A protein mixture of 30–50 μg was loaded and separated by SDS-PAGE and transferred onto the polyvinylidene fluoride printed membrane (FFP39, Beyotime). Membranes were blocked in Tris-buffered saline plus 0.1% Tween 20 containing 5% skim milk for 1–2 h. Next, the following primary antibodies were incubated overnight at 4 °C. As secondary antibody, membranes were incubated with secondary antibodies for 1 h at room temperature. Signal was detected using enhanced chemiluminescence (ECL) (abs921, Absin), and captured using Bio-Rad ChemiDoc gel imaging system. Protein expression was quantified using analysis software such as ImageJ. The images presented are representative of three separate experiments. Quantitative real-time PCR (qPCR) Total RNA was isolated by SteadyPure Universal RNA Extraction Kit (AG21017, Accurate Biology). The Evo M-MLV RT Premix for qPCR (AG11706, Accurate Biology) was used for reverse transcription to obtain cDNA. Quantitative PCR using the dye method was performed on the quantitative PCR instrument CFX ConnectTM (Bio-Rad), using the SYBR Green Premix Pro Taq HS qPCR Kit (AG11701, Accurate Biology). The relative expression of mRNA compared with the house keeping gene and the folding change compared with control were measured via the 2ΔΔCt method. All primers’ sequences available in Supplementary Table S1. Flow cytometry For flow cytometry analysis, the single cells were stained with Fixable Viability Dye eFluor 450, followed by incubation with the indicated antibodies listed in Supplementary Table S1. For cytokine staining, cells were first stimulated with The Cell Stimulation Cocktail (2430454, Thermo Fisher), and fixed/permeabilized using Foxp3/Transcription Factor Staining Buffer Set (2473720, Thermo Fisher), then stained with APC-conjugated anti-IFN-γ. Flow cytometry was performed on the BD FACSCanto II flow cytometer via BD FACSDiva software (BD Biosciences), and data were analyzed using FlowJo software v10.7.1. Gating strategies was shown in the Supplementary Information. Murine BMDCs and spleen-derived T cells generation Bone marrow cells were taken from the fibula and tibia of 8–10-week-old mice. After treatment with RBC lysis buffer (420301, BioLegend), the remaining cells were induced with the addition of 20 ng/ml mGM-CSF (AF-315-03, PeproTech) and 10 ng/ml mIL-4 (214-14, PeproTech). After 7 days of induction culture, LPS was added to the culture medium for 24 h to generate mature BMDCs. For spleen-derived T cells, we harvested spleens from B16-F10-OVA tumor-bearing C57BL/6 J and OT-1 mice, mechanically dissociated them through 70 μm cell strainers, lysed red blood cells and obtained single-cell suspensions of T cells. Stable cell line generation and cell transfection The shRNAs for Ptpn6, OVA overexpression plasmid and the siRNA for Jak1 were obtained from TSINGKE biological technology (Beijing, China). The siRNA for Ptpn6 used in this study was synthesized by RIBOBIO (Guangzhou, China). Transfection was performed as previously described [17]. Western blotting was used to detect changes in SHP1, OVA and JAK1 protein levels to confirm transfection efficiency. Co-culture and T cell proliferation assay DC2.4-sgCtrl/Ptpn6 or CTL/cKO-BMDCs were treated with LPS and OVA and then co-cultured with isolated OT-1 mouse splenic T cells at a ratio of DC:T cell = 1:20. For CFSE detection, T cells were stained with the CFSE Cell Division Tracker Kit (423801, Biolegend) before co-culture. After 48 h, flow cytometry was used to assess T cell CFSE dilution and TCF-1 expression levels. Additionally, we isolated splenic T cells from B16-F10-OVA tumor-bearing C57BL/6 J mice and co-cultured them with DC2.4-sgCtrl/Ptpn6 cells. After 48 h, we analyzed TCF-1 expression in T cells by flow cytometry. Mouse experiments For in vivo experiments, mice were assigned to experimental groups by randomization. 2 × 105 tumor cells mixed with DC2.4 cells were injected subcutaneously into mice at a ratio of 1:1. For the vaccine experiments, Vitamin E ((+)-α-tocopherol) (T1539, Sigma) was diluted with soybean oil (S7381, Sigma), using the TNBC cancer-specific antigen alpha-lactalbumin (αLA) as a vaccine, treatments were given to each group as single agents or in combination with VitE. αLA was dissolved in ethanol and emulsified 1:1 with complete Freund’s adjuvant (CFA) for the first immunization. Mice were immunized s.c. with the emulsion, followed by two boosts at 10-day intervals using incomplete Freund’s adjuvant (IFA) instead of CFA. Vehicle or VitE (0.2 mg/mouse) was injected adjacent to the vaccine site at each immunization, and 2 × 105 EMT6 cells were injected in the mammary fat pad of mice on day 30. Tumor volume was measured every 2–3 days using the following formula: V = (length × width2)/2. Moreover, CTL and cKO mice were subcutaneously injected with 2×10⁵ B16-F10-OVA cells in the dorsal flank. Tumors were harvested on day 20 for flow cytometry analysis. No animals or samples were excluded from the analysis. All mice that met the basic health criteria at the start of the experiment were included. Blinding was not performed in this study. Isolation of single cells from tumor tissue Tumor samples were isolated from tumor model in mice and cut with sterile surgical scissors. Then, 1 mg/ml collagenase I (C8140, Solarbio) and 25 µg/ml DNase I (10104159001, Sigma-Aldrich) were used for digestion. The digested solution was passed through a cell filter (70 μm), red blood cells were removed with RBC lysis buffer, and single cells were collected for flow cytometry analysis. For tumor-associated dendritic cells (TADCs), cells were magnetically enriched using CD11c MicroBeads Ultrapure Kit (130-125-835, Miltenyi Biotec). 1 ml TRIzol reagent (15596026CN, Thermo Fisher) was added to every 5×106 cells, and the cells were repeatedly blown until the solution was cool and non-viscous for subsequent RNA-seq analysis. CyTOF analysis of immune cells CyTOF analyses were performed by PLTTech Inc. (Hangzhou, China) according to the previously described methodology [18]. Flowjo pre-processing: remove beads (140Ce-), beads (191Ir+ 193Ir+), dead cells (194Pt-), adherent cells (Event_length < 20), and select single, live, complete cells. CD45+ immune cells were then circled for further analysis. The immune cell types were identified via nonlinear dimensionality reduction [T-distributed stochastic neighbor embedding (tSNE)] and then density clustering was performed [19]. RNA- seq Library construction and sequencing were performed by Novogene Co., LTD. (Beijing, China). The gene expression value of RNA-seq was determined by FPKM, expected number of Fragments Per Kilobase of transcript sequence per Millions base pairs sequenced [20]. Prior to differential gene expression analysis, the read counts were adjusted by edgeR program package through one scaling normalized factor. Differential expression analysis of two conditions was performed using the edgeR R package (3.22.5). pvalue < =0.05 and |log2(foldchange)| >= 1 were set as the threshold for significantly differential expression. Statistical analysis No statistical methods were used to predetermine sample size. Sample sizes for animal studies were based on pilot experiments and mouse availability. In vitro experiments were performed with at least three independent replicates. All statistical analyses were performed via GraphPad Prism v.8.0 software. All data are presented as SEM mean values unless otherwise specified. Statistical significance of the differences between two experimental conditions was determined by the unpaired two-tailed Student t test, and comparisons between more than two groups were calculated by one-way analysis of variance (ANOVA). Statistical significance was set at ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Results SHP1 inhibits the antigen-presenting capacity and activation of DC in vitro Studies have shown that SHP1 plays a key role in DC function and T cell response [21–24]. As precursor cells, CD14⁺ monocytes can differentiate into DCs. Therefore, we examined the infiltration of CD14⁺SHP1⁺ cells in TNBC tissue microarrays and classified the TNBC samples into high and low co-expression groups of SHP1 (red) and CD14 (green) based on the median co-localization positive rate (Fig. 1A). While CD14 is not a definitive marker for mature DCs, the presence of CD14⁺SHP1⁺ cells in the TME may reflect the abundance of monocytic lineage cells, including monocytes and potential DC precursors. Further IHC analysis of CD8 expression in these two groups revealed that, compared to the low co-expression group, the high co-expression group of SHP1 and CD14 generally exhibited lower CD8 levels (Fig. 1B). This suggested that SHP1 expression in CD14⁺ monocytic cells (which include DC precursors) is associated with reduced CD8⁺ T cell infiltration in the TME. SHP1 inhibits DC activation and antigen presentation. A Representative TMA samples from TNBC patients were subjected to immunofluorescence staining using antibodies against SHP1 and CD14. B Representative IHC staining images and analysis of CD8 H-scores difference between high and low co-expression group (n = 24). C Western blot analysis of SHP1 protein levels confirms the knockdown efficiency of Ptpn6 in DC2.4 cells. D Flow cytometric analysis of H2Kb-SIINFEKL mean fluorescence intensity (MFI) following Ptpn6 knockdown in DC2.4 cells (n = 3). E Western blot analysis of SHP1 protein levels confirms Ptpn6 knockout efficiency in DC2.4 cells. F Representative data of flow cytometry analysis and quantification of H2Kb-SIINFEKL (n = 3). G Flow cytometric analysis of CD40 mean fluorescence intensity (MFI) following Ptpn6 knockdown in DC2.4 cells (n = 3). H Representative data of flow cytometry analysis and quantification of CD40 (n = 3). I Flow cytometric analysis of MHC-II mean fluorescence intensity (MFI) following Ptpn6 knockdown in DC2.4 cells (n = 3). J Representative data of flow cytometry analysis and quantification of MHC-II (n = 3) in different groups of DC2.4 cells (n = 3). Data are presented as the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. To assess the influence of SHP1 on DC activation/antigen presentation and its impact on T cells, we knocked down the SHP1-encoding Ptpn6 gene in DC2.4 cells (Fig. 1C). We measured the expression level of OVA peptide bound to the H-2Kb of MHC-I (H2Kb-SIINFEKL) on OVA-loaded DCs. There was an increase of H2Kb-SIINFEKL on DC2.4-shPtpn6 cells compared to DC2.4-shCtrl cells (Fig. 1D, Fig. S1A). Also, knockout of the Ptpn6 gene in DC2.4 cells (Fig. 1E) increased H2Kb-SIINFEKL expression (Fig. 1F).CD40 is a critical co-stimulatory receptor on DCs, important for their full maturation and ability to prime T cell responses [25]. Inhibition of SHP1 in DCs led to a marked upregulation of CD40 expression (Fig. 1G, Fig. S1B and Fig. 1H). Mature DCs acquire an enhanced immunostimulatory capacity, characterized in part by upregulated surface expression of MHC class II molecules [26]. Similarly, knockdown or knockout of SHP1 elevated MHC-II expression (Fig. 1I, Fig. S1C and Fig. 1J), indicating that SHP1 restrains DC maturation and thereby limits their cross-presentation capacity. Collectively, we demonstrated that genetic ablation of SHP1 in DCs promotes their activation and antigen cross-presentation capacity in vitro. SHP1 of DC enhances immune escape of B16-F10 and EMT6 tumor cells in vivo To evaluate the role of DC SHP1 in tumor progression in vivo, we established a tumor-bearing mouse model by co-injecting B16-F10 or EMT6 tumor cells with DCs at a 1:1 ratio. DC2.4-shPtpn6 cells significantly suppressed tumor growth in a murine melanoma model (Fig. 2A, B and Fig. S2A). In addition, overall survival and tumor-free survival were both significantly prolonged in mice injected with DC2.4-shPtpn6 cells (Fig. 2C, D). To validate this finding in an independent tumor model, we transfected BMDCs with siPtpn6 (Fig. 2E) and co-inoculated with EMT6 cells into mouse mammary fat pads. Knockdown of SHP1 in BMDCs similarly conferred significant suppression of orthotopic EMT6 mammary tumor growth (Fig. 2F, G and Fig. S2B). The overall survival and tumor-free survival of mice were also extended after silencing SHP1 of BMDCs (Fig. 2H, I). Genetic ablation of SHP1 specifically in DCs conferred potent anti-tumor immunity, as evidenced by significantly slower B16-F10-OVA tumor progression in DC-conditional SHP1 knockout (cKO) mice compared to CTL group (Fig. S2C, D, and Fig. 2J–M). Together, these data indicated that targeting SHP1 in DCs elicits robust anti-tumor immunity sufficient to suppress B16-F10 and EMT6 tumor cells in vivo. DC SHP1 promotes the growth of tumor cells in mice. Growth curves (A) and tumor size (day 20) (B) of subcutaneous B16-F10 tumors in mice injected with either B16-F10 cells alone or in combination with different DC2.4 cells (n = 5). Kaplan-Meier curve showing the OS (C) and tumor-free survival (D) of mice transplanted with either B16-F10 cells alone or in combination with different DC2.4 cells (n = 5). E Western blot analysis of SHP1 protein levels in BMDCs-siCtrl and BMDCs-siPtpn6. Growth curves (F) and tumor size (day 26) (G) of subcutaneous tumors in mice injected with EMT6 cells alone or EMT6 cells combined with BMDCs-siCtrl or BMDCs-siPtpn6 (n = 5). Kaplan-Meier curve showing the OS (H) and tumor-free survival (I) of mice transplanted with either EMT6 cells alone or in combination with different BMDCs (n = 5). J Validation of OVA-overexpressing B16-F10 cell line and schematic diagram of subcutaneous tumor model in conditional knockout mice. Tumor growth curves of B16-F10-OVA in CTL and cKO mice (K), tumors from CTL and cKO mice (L), and tumor sizes at day 20 (M) (n = 4-5). Data are presented as the mean ± SEM of three independent experiments. ns not significant; *, P < 0.05; **, P < 0.01. Inhibition of SHP1 on DC elicits potent anti-tumor immunity through remodeling of immune cell subsets in the TME To dissect the underlying mechanisms by which SHP1 of DC promotes immune escape, we isolated B16-F10 and EMT6 tumor tissues from mice. Flow cytometry analysis showed that inhibiting of SHP1 increased tumor infiltration of CD40+ DCs (Fig. 3A, B). Moreover, tumor-infiltrating DCs from cKO mice exhibited substantially higher frequencies of both H2Kb-SIINFEKL (Fig. 3C) and CD40 (Fig. 3D) populations compared to CTL controls. To assess whether pharmacological inhibition of DC SHP1 suppresses tumor growth, we treated EMT6 tumor-bearing mice with VitE, a compound we identified as a DC-SHP1 inhibitor [14]. Specifically, the TNBC-associated antigen αLA [27] was emulsified with complete or incomplete Freund’s adjuvant (CFA/IFA) to enhance its immunogenicity [28]. Combined administration of VitE, the αLA vaccine elicited potent anti-tumor efficacy, leading to marked inhibition of EMT6 tumor cells (Fig. 3E). To characterize the tumor immune landscape, EMT6 tumor specimens were analyzed by CyTOF. Based on the canonical cell surface markers (Supplementary Table S2), we defined 29 major cell clusters (Fig. 3F). Interestingly, the number of effector CD8+ T cells (C02 and C03), effector CD4+ T cells (C05 and C10) and B cells (C11 and C17) were obviously higher in the αLA + VitE group. Meanwhile, the frequencies of macrophages (C16) and monocytes/neutrophils cells (C21-24) were further reduced by VitE (Fig. 3G, H). The several cells mentioned earlier play a role in the anti-tumor immune response, while the latter cells play a dual role in the tumor [29]. Inhibiting SHP1 with VitE altered the proportion of various immune cells in TME, possibly leading to the formation of an enhanced anti-tumor immune microenvironment. Inhibition of SHP1 change TME in proportion of anti-tumor immune cells. Representative data of flow cytometric analysis of CD40 expression on CD11c+ MHC-II+ DCs in B16-F10 (A) and EMT6 (B) tumor tissues (n = 3). Representative data of flow cytometric analysis of H2Kb-SIINFEKL (C) (n = 4) and CD40 (D) (n = 4) expression on CD11c+ MHC-II+ DCs in B16-F10-OVA tumor tissues from CTL and cKO mice. E Growth curves of subcutaneous EMT6 tumors in mice treated with vehicle, αLA, or combined VitE by s.c. at days 10, 20, and 30 before tumor cells were injected subcutaneously (n = 10). F A heatmap showing the differential expression of 41 immune markers in the 25 cell clusters. Certain clusters were identified as known cell types according to typically expressed markers. The gray bar chart shows the proportion of each cluster in the total cluster data set. The far right part is marker expression intensity scale (red means marker expression intensity is 1, blue means marker expression intensity is 0). G Visualised t-SNE map of definition of CD45+ immune cells from CyTOF data of three tumor tissue samples in different treatment groups. H Frequency diagram of immune cell subsets in the different treatment groups. I tSNE plots color-coded for expression of MHC-II marker in immune cells in different treatment groups. Each dot represents an individual cell. The color scale indicates the MHC-II expression intensity on a per-cell basis (blue: low; red: high). Data are presented as the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. According to the visual t-SNE diagram of CyTOF data, the expression of classical markers MHC-II increased in the αLA + VitE group (Fig. 3I). These results indicated that inhibition of DC SHP1 licensed DC maturation thereby unleashing potent anti-tumor immunity. SHP1 deficiency enhances the activation and antigen presentation of DCs through the IFN-γ -JAK1/2-STAT1 signaling pathway To help define how DC SHP1 regulates its antigen presentation capacity, we extracted DCs from tumor tissues of mice treated with solvent blank control, αLA vaccine and αLA + VitE for RNA-seq analysis. We obtained three groups of differentially expressed genes (DEGs). As shown in the Venn diagram, taking the intersection of the three groups of DEGs, 252 overlapping genes were found (Fig. 4A). GO cluster analysis revealed that antigen processing and presentation were enriched among the top biological processes (Fig. 4B). Besides, KEGG analysis revealed that DC SHP1 may affect antigen processing and presentation by regulating protein processing related pathways (Fig. 4C). Next, genes related to antigen presentation in the DEGs of αLA vs. αLA + VitE group were screened and analyzed, and the results showed that Ifng expression was significantly upregulated in the αLA + VitE group (Fig. 4D). To validate this observation, the transcriptional levels of several antigen presentation-related genes were measured in BMDCs-siPtpn6 cells in vitro. Evidently, inhibition of SHP1 enhanced the expression of Ifng (Fig. 4E), suggesting a potential involvement of Ifng in the mechanism by which SHP1 regulates antigen presentation. The effect of SHP1 on DC antigen presentation is related to the activation of JAK1/2-STAT1 pathway by IFN-γ. A Venn diagram of DEGs from RNA-seq data of DCs sorted from mouse tumors in different treatment groups. List of the most relevant GO terms (B) in each cluster of DEGs together with the enrichment significance cores and dot plot showing KEGG pathway (C) enrichment analyses of DEGs. D Volcano plots showing the number of antigen presentation-related DEGs based on log2Fold change and P value in αLA+VitE vs. αLA. Red dots indicate the up regulated genes, and blue dots represent the down-regulated genes. E qPCR analysis of the relative mRNA expression levels of Ifng, Tap1, Cd74, and H2-Ab1 (n = 3). F Western blot analysis of the indicated proteins in DC2.4-sgCtrl and DC2.4-sgPtpn6 cells. G qPCR analysis of the relative mRNA expression levels of Ifng, H2-K1, Erap1, Cd74, and H2-Ab1 in BMDCs of CTL and cKO mice (n = 3). H Western blot analysis of the indicated proteins in BMDCs of CTL and cKO mice treated with IFN-γ (100 ng/ml). I Western blot analysis of JAK1 protein levels in DC2.4 transfected with control siRNA and siJak1. Flow cytometry analysis of H2Kb-SIINFEKL (J), CD40 (K), and MHC-II (L) expression on DC2.4 cells in different treatment groups. Data are presented as the mean ± SEM of three independent experiments. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. It has been reported that IFN-γ activates the JAK1/2-STAT1 pathway to promote DC maturation and enhance MHC-I-mediated cross-presentation [30, 31]. We assessed the impact of SHP1 deficiency on the activation of the JAK1/2-STAT1 signaling pathway in DC. As shown in the results, IFN-γ and the phosphorylation levels of JAK1 (p-JAK1), JAK2 (p-JAK2), and STAT1 (p-STAT1-701) were increased in DC2.4-sgPtpn6 cells (Fig. 4F and Fig. S3A). In addition, the expression of Ifng in BMDCs of cKO mice was indeed increased (Fig. 4G and Fig. S3B). Similarly, the IFN-γ, p-STAT1-Tyr701, p-JAK1 and p-JAK2 increased after SHP1 deletion in cKO mice compared to CTL (Fig. 4H). Next, we found that silencing Jak1 in DC2.4-sgPtpn6 cells (Fig. 4I) significantly reduced the number of cells expressing H2Kb-SIINFEKL, CD40 and MHC-II, neutralizing the effect caused by SHP1 knockout (Fig. 4J–L, and Fig. S3C–E). These results demonstrate that SHP1 deficiency upregulates Ifng expression and that the increased IFN-γ subsequently activates JAK1/2-STAT1 signaling, consistent with previous reports [30, 31], ultimately promoting DC antigen presentation. Targeting SHP1 suppresses tumor immune evasion through the expansion of effector CD8+ T cells Given the essential role of DCs in priming antigen-specific T cells, we investigated whether DC SHP1 regulates CD8+ T cell responses. Indeed, DC2.4-sgPtpn6 and cKO-BMDC potently induced proliferation of co-cultured OT-1 T-cells (Fig. 5A, B). These findings demonstrated that SHP1 inhibition potentiates DC function, effectively promoting T-cell expansion in vitro and consequently augmenting immune responses. According to the visual t-SNE diagram, the expression of marker CD8 increased in the αLA + VitE group (Fig. 5C). These findings indicated the inhibition of SHP1 mediated by VitE increased the abundance of CD8+ T cells in vivo and facilitated their activation. Further analysis of tumor tissues showed that the infiltration of CD8+ T cells (Fig. 5D, E and Fig. S4A), especially IFN-γ+CD8+ T cells (Fig. 5F, G), a subset of cytotoxic T cells that produce IFN-γ to kill tumor cells [32], had increased in tumors after SHP1 blockade. Moreover, cKO tumors exhibited significantly higher frequencies of CD8+ T cells and IFN-γ+CD8+ T cells (Fig. 5H, I), accompanied by a marked increase in OVA-specific CD8+ T cell infiltration (Fig. 5J). These findings suggested that targeting SHP1 enhances DC-mediated cross-presentation of tumor antigens, thereby promoting efficient CD8+ T cell cross-priming. DC SHP1 inhibits the proliferation and function of anti-tumor T cells. CFSE-dilution analysis of OT-1 T cells co-cultured with DC2.4 (A) and BMDCs (B) (n = 3). C tSNE plots color-coded for expression of CD8 marker in different treatment groups. Each dot represents an individual cell. The color scale indicates the CD8 expression intensity on a per-cell basis (blue: low; red: high). Flow cytometric profiling of tumor-infiltrating CD8+ T cells populations in B16-F10 (D) and EMT6 tumor models (E) (n = 3). Flow cytometric profiling of tumor-infiltrating IFN-γ+CD8+ T cells populations in B16-F10 (F) and EMT6 tumor models (G) (n = 3). Flow cytometric profiling of tumor-infiltrating CD8+ T cells (H) (n = 3), IFN-γ+CD8+ T cells (I) (n = 4) and OVA-tetramer+ CD8+ T cells (J) (n = 3) populations in B16-F10-OVA tumors. Data are presented as the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Targeting SHP1 effectively enhances the formation of antigen-specific memory T cells Memory T cells are defined by their ability to rapidly and robustly re-expand and acquire effector functions upon re-encounter with tumor-associated antigens, enabling efficient tumor clearance [33]. DCs play key roles in the formation of memory T cells [16, 34]. We found that inhibiting SHP1 promoted the proportion of TCM (CD62L+CD44+) in tumors (Fig. 6A, B). Also, VitE increased the formation of TCM induced by αLA vaccine in EMT6 models (Fig. 6C). It is strongly supported that inhibiting SHP1 on DC promoted the infiltration of memory T cells in TME, but the detailed mechanism remains unclear. DC SHP1 regulates TCF-1-mediated central memory CD8+ T cell differentiation. Flow cytometric profiling of tumor-infiltrating memory CD8+ T cells in B16-F10 (A) and EMT6 (B) tumor tissue from mice treated with different DC2.4 cells or BMDCs (n = 3). (C) Flow cytometric profiling of tumor-infiltrating memory CD8+ T cells in EMT6 tumor tissue from mice treated with vehicle, αLA, or αLA + VitE. D Representative IHC staining images and analysis of TCF-1 H-scores difference between high and low co-expression group of SHP1 and CD14 groups (n = 21). Flow cytometry analysis of TCF-1 expression in splenic T cells from B16-F10-OVA tumor-bearing mice (E) (n = 3) and OT-1 mice (F) co-cultured with DC2.4-sgCtrl or DC2.4-sgPtpn6. Flow cytometric profiling of tumor-infiltrating TCF-1+CD8+ T cells populations in EMT6 tumor tissue from mice treated with different BMDCs (G) (n = 3) or αLA and VitE (H). (I) Flow cytometric profiling of tumor-infiltrating TCF-1+CD8+ T cells populations in B16-F10-OVA tumors from CTL or cKO mice (n = 3). Data are presented as the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Previous studies have found that the longevity and secondary immune response ability of memory CD8+ T cells are regulated by transcription factor TCF-1, which promotes the secondary immune response process of TCM [35]. IHC analysis of TCF-1 expression in TNBC samples revealed significantly lower TCF-1 levels in the group with high co-expression of SHP1 and CD14 (Fig. 6D), suggesting that SHP1 in CD14⁺ monocytic cells may suppress the expression of the TCF-1. The results of the in vitro co-culture experiment demonstrated that SHP1 inhibition significantly upregulated TCF-1 expression in T cells (Fig. 6E, F). Our study showed that BMDCs-siPtpn6 and DC2.4-shPtpn6 cells treated groups had more CD8+ T cells expressing TCF-1 than control groups (Fig. 6G and Fig. S5A) and VitE increased the expression of TCF-1 in CD8+ T cells (Fig. 6H). Consistently, TCF-1+ T cell infiltration was significantly increased in B16-F10-OVA tumors from cKO mice compared to CTL mice (Fig. 6I). In summary, both in vivo and in vitro experiments demonstrated that SHP1 inhibition enhanced the accumulation of memory T cell populations within tumors. This process may be related to SHP1 inhibiting TCF-1 expression of T cells by interfering with antigen presentation of DC cells. Discussion Studies have found that VitE enhances the therapeutic effect of PD-1/PD-L1 inhibitors on tumors by activating DC and VitE effectively inhibits DC SHP1. Compared with other cells, SHP1 protein is highly expressed in DC, and SHP1 is positively correlated with PD-L1 expression in breast cancer. Targeting SHP1 may interfere with the occurrence of breast cancer by enhancing DC antigen presentation [14]. By knocking down and knocking out the Ptpn6 gene of DC2.4 cells to inhibit the expression of SHP1, we verified that SHP1 indeed inhibited DC activation and maturation, and reduced the ability of antigen presentation in vitro (Fig. 1C–J). Blocking SHP1 of DC cells contributes to resistance to tumor growth in vivo (Fig. 2A, F and K). In addition, VitE inhibited SHP1 and changed the infiltration of immune cells. Such changes in cell subsets are generally considered to be conducive to the formation of anti-tumor immune microenvironment [29]. Exploring the key downstream mechanisms of targeting SHP1 provides a basis for finding safe and effective activation of DC immunity. RNA-seq data analysis showed that SHP1 was closely related to the antigen presentation of DC (Fig. 4B) and this process was mediated by stimulation of the JAK1/2-STAT1 signaling pathway (Fig. 4F, H). JAK1 expression levels had significant positive correlations with infiltrating levels of CD8+ T cells, CD4+ T cells, and DCs in breast cancer [36]. STAT1 is required for differentiation and maturation of DC [37]. In addition, studies have demonstrated the ability of DC intrinsic IFN-γ-JAK1-STAT1 signaling to induce PD-L1 and drive peripheral Treg cells production and tolerance [38]. Classically, JAK inhibitors are characterized as immunosuppressive agents due to their ability to block the JAK-STAT pathway, which underpins their therapeutic use in autoimmune and inflammatory diseases [39]. However, emerging evidence suggests a more nuanced role in the context of cancer immunotherapy. JAK inhibitor combined with ICI reversed T cell depletion, increased the number of anti-tumor T cells and natural killer cells, and significantly enhanced the efficacy of ICI in the treatment of lung cancer and lymphoma [40, 41]. Therefore, the complex role of JAK-STAT pathway in tumor immunity needs to be studied in the future. Consistent with a previous report demonstrating that SHP1 negatively regulates antigen cross-presentation in DCs, though through a distinct underlying mechanism [24], our findings further support the role of SHP1 as a key checkpoint in DC-mediated T cell immunity. Memory immune cells are the basis of immune memory and secondary response. Memory T cells are composed of multiple subgroups, including effector memory T cells and TCM in the circulatory system. Studies have shown that TCF-1 determines the secondary response ability of CD8+ memory T cells, and the loss of TCF-1 can affect the secondary immune response ability of TCM [35]. Our results showed that SHP1 reduced the amount of TCM in tumors (Fig. 6A–C), and affected the secondary immune response ability of memory T cells by inhibiting the expression of TCF-1 (Fig. 6E–I), but the detailed molecular mechanism needs further experimental demonstration. In conclusion, targeting DC-SHP1 enhances the secretion of IFN-γ, which in turn activates the JAK1/2-STAT1 signaling pathway. This cascade licenses DC activation antigen-presenting function, thereby driving the expansion and functional enhancement of memory T cells and intratumoral CD8+ T cells, particularly the TCF-1+progenitor subset—culminating in effective disruption of tumor immune evasion and enhanced responsiveness to immunotherapy. Supplementary information Supplementary Information Acknowledgements We would like to thank Lingsha Qin for essential technical support and assistance in flow cytometry, especially the excellent assistance in cells sorting. Author contributions YG: Conceptualization, Data curation, Formal analysis, Methodology, Software, Writing-original draft, Writing-review & editing. YL: Conceptualization, Data curation, Formal analysis, Methodology, Writing-original draft. WY: Conceptualization, Data curation, Formal analysis, Methodology, Software. GZ: Data curation, Formal analysis, Investigation, Methodology, Software. BL: Conceptualization, Data curation, Formal analysis, Investigation. JH: Conceptualization, Data curation, Formal analysis. JZ: Conceptualization, Data curation, Formal analysis. XY: Conceptualization, Data curation, Formal analysis. LW: Conceptualization, Data curation, Formal analysis, Methodology. XT: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Supervision. YZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing-review & editing. Funding This work was supported by the National Natural Science Foundation of China (82304532), Guangdong Basic and Applied Basic Research Foundation (2024A1515220102), and the Foundation for High-level Talents in Higher Education of Qingyuan People’s Hospital. Data availability The RNA-seq data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under the BioProject accession number PRJNA1304671. Conflict of interest The authors declare no competing interests. Ethics approval The study was approved by the Ethics Committee of the Affiliated Qingyuan Hospital of Guangzhou Medical University, approval number: LAEC-2022-027. All animal experiments have complied with ARRIVE Guidelines, the U.K. Animals (Scientific Procedures) Act, 1986 and the EU 2010/63/ EU for animal experiments, or the National Research Council’s Guidelines for the Care and Use of Laboratory Animals. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Gao Yu, Yusheng Liang, Weize Yu, Gaojian Zhuang. Contributor Information Xiaoming Tan, Email: txmwmh@163.com. Yuan Zhang, Email: zhangyuanlazy@gzhmu.edu.cn. Supplementary information The online version contains supplementary material available at 10.1038/s41389-026-00627-z. References Associated Data Supplementary Materials Supplementary Information Data Availability Statement The RNA-seq data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under the BioProject accession number PRJNA1304671.